In the Boardroom
Refine Search
Biotechnology
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
Biotechnology
Boston, Massachusetts-based biotech Cue Biopharma
has appointed industry veteran Lucinda Warren as chief business officer (CBO). 10 September 2024
Biotechnology
US RNA medicines developer Stoke Therapeutics has announced the appointment of Eric Olson as chief business officer. 7 September 2024
Pharmaceutical
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biotechnology
LakeShore Biopharma (Nasdaq: LSB), previously known as YS Biopharma, has appointed Xu Wang as its new chief executive officer. 5 September 2024
Biosimilars
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Biotechnology
Cambridge, UK-based clinical-stage biotech CellCentric has appointed Andy Fergus as chief development officer. 5 September 2024
Pharmaceutical
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Pharmaceutical
US metabolic health company Skye Bioscience has announced the appointment of Puneet Arora as chief medical officer (CMO). 3 September 2024
Biotechnology
A series of key leadership changes have been announced on Tuesday at Dyne Therapeutics, a muscle disease company developing therapeutics for people living with genetically-driven diseases. 3 September 2024
Biotechnology
Orbital Therapeutics today announced the appointment of Ron Philip as chief executive (CEO) and a member of its board of directors. 3 September 2024
Biotechnology
UK-based Amphista Therapeutics—which calls itself a leader in next generation targeted protein degradation (TPD) approaches—has named Antony Mattessich its new chief executive (CEO) and member of the board of directors. 3 September 2024
Pharmaceutical
Belgian drugmaker UCB has appointed Nico Reynders as general manager of its UK & Ireland affiliate. 2 September 2024
Biotechnology
US gene therapy biotech Tern Therapeutics has announced its launch and closing of a $15 million financing. 28 August 2024
Biotechnology
Texas, USA-based Coya Therapeutics announced that Arun Swaminathan has been promoted to the role of chief executive (CEO) effective November 1, 2024. 22 August 2024
Biotechnology
BioMarin Pharmaceutical (Nasdaq: BMRN) has announced key leadership changes, appointing Greg Friberg as chief research and development officer, and James Sabry as chief business officer. 21 August 2024
Biotechnology
US biotech Cidara Therapeutics has appointed sector veteran Jim Beite as its chief business officer (CBO). 21 August 2024
Biotechnology
California, USA-based clinical-stage biopharmaceutical company 89bio has appointed Francis Sarena as chief operating officer (COO), effective August 5, 2024. 20 August 2024
Biotechnology
USA-based biotech Tiziana Life Sciences today announced the appointment of Ivor Elrifi as its chief executive (CEO), effective immediately. 19 August 2024
Pharmaceutical
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
Biotechnology
ReAlta Life Sciences, a US biopharma seeking to address life-threatening rare and acute inflammatory diseases by rebalancing the inflammatory response, has announced the appointment of Ellen Lubman as chief business officer (CBO). 29 July 2025
Pharmaceutical
Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective August 7, 2025. Mr Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective August 7. 29 July 2025
Pharmaceutical
US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief medical officer and head of development, effective August 1, 2025. 26 July 2025
Pharmaceutical
UK-based Rosemont Pharmaceuticals has appointed a new chair with a wealth of experience in the US pharma market. 23 July 2025
Biotechnology
UK government-backed Cell and Gene Therapy Catapult (CGT Catapult), a tech and innovation organization specializing in the advancement of the cell and gene therapy industry, has appointed Ed Samuel as its chief operations officer (COO). 23 July 2025
Pharmaceutical
French pharma Ipsen (Euronext: IPN) today announced the following changes to its executive committee: 23 July 2025
Biotechnology
After 13 years at the helm of the UK’s BioIndustry Association, Steve Bates has tendered his resignation as chief executive of the BIA to take up a newly created position announced today as executive chair for the Office of Life Science within the UK government. His last day at the BIA will be Friday, September 26, 2025. 23 July 2025
Pharmaceutical
Neuraxpharm Group, a privately-held German specialty pharma focused on central nervous system (CNS) disorders, today announced the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed head of commercial, Avendran Naidu, as the company continues to expand globally. 22 July 2025
Pharmaceutical
The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as vice president of the trade group. 22 July 2025
Biotechnology
NodThera, a privately-held biotech working in chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, has announced the appointment of Jyothis George as chief medical officer (CMO), effective immediately. 21 July 2025
Biotechnology
German mRNA specialist BioNTech has announced that Ryan Richardson will step down from his position as chief strategy officer and member of the management board. 18 July 2025
Biotechnology
US biotech TRIO Pharmaceuticals has announced the appointment of Patrick Doyle as chief executive (CEO effective immediately. 18 July 2025
Biotechnology
Scottish biotech Trogenix has announced two senior appointments as the company advances its pipeline towards the clinic. 18 July 2025
Pharmaceutical
Bayer is giving chief executive Bill Anderson more time to deliver on his ambitious efforts to reshape the German group, extending his contract by three years to March 2029. The move signals strong support from the company’s supervisory board, which voted unanimously in favor of the renewal. 17 July 2025
Biotechnology
Bharatt Chowrira has stepped down from his role as chief executive (CEO) and board member at US biopharma PureTech Health. 16 July 2025
Biotechnology
US biotech Tract Bio has appointed Chris Galloway as chief medical and development officer, as it prepares for an investigational new drug filing for its lead oncology candidate, TP-101, within the next 18 months. The Boston-based company is also expanding its board with two senior figures from the oncology and biotech world: Mark Adler and Kristiina Vuori. 15 July 2025
Biotechnology
Swiss clinical-stage CNS disease specialist Synendos Therapeutics has named Dr George Garibaldi as its chief medical officer (CMO). 15 July 2025
Biotechnology
USA-based Uniquity Bio has appointed industry veteran Will Kane as its president and chief executive. 15 July 2025
Biotechnology
BrainXell, a US biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, has announced the appointment of Katherine Vega Stultz as its new chief executive and board director. 11 July 2025
Pharmaceutical
French biotech Inventiva has changed up its executive team as it continues to bet on experimental MASH therapy lanifibranor, bringing in new leadership to steer the drug through its late-stage development and potential regulatory filings. 10 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze